<DOC>
	<DOCNO>NCT00010036</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine carboplatin irinotecan treating patient glioblastoma multiforme .</brief_summary>
	<brief_title>Carboplatin Plus Irinotecan Treating Patients With Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) carboplatin irinotecan patient glioblastoma multiforme . ( Phase I close accrual 6/24/02 ) - Determine toxic effect regimen patient . - Determine objective response patient treat establish MTD regimen . - Determine time tumor progression survival patient treat regimen . OUTLINE : This dose-escalation study . Patients phase II portion study stratify accord age ( 60 vs 60 ) , ECOG performance status ( 0-1 v 2 ) , extent resection ( total v subtotal ) . ( Phase I close accrual 6/24/02 ) Within 4 week surgery , patient receive carboplatin IV 30 minute follow irinotecan IV 90 minute day 1 . Treatment repeat every 4 week maximum 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos carboplatin irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient accrue receive carboplatin irinotecan recommend phase II dose . ( Phase I close accrual 6/24/02 ) After chemotherapy , patient undergo radiotherapy . Patients follow 30 day . PROJECTED ACCRUAL : A total 24-107 patient ( 3-54 phase I 21-53 phase II ) accrue study . ( Phase I close accrual 6/24/02 )</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm glioblastoma multiforme Measurable disease No CNS metastases carcinomatous meningitis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Karnofsky 70100 % Life expectancy : At least 12 week Hematopoietic : Granulocyte count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin great 1.5 mg/dL SGOT great 3 time upper limit normal ( ULN ) ( 5 time ULN liver involvement ) No know Gilbert 's syndrome Renal : Creatinine great 1.5 mg/dL Cardiovascular : No myocardial infarction within past 6 month No congestive heart failure require therapy Other : HIV negative No active uncontrolled infection No psychiatric disorder would preclude study No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No uncontrolled diabetes mellitus ( i.e. , random blood sugar 200 mg ) No severe disease would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy biologic therapy No concurrent sargramostim ( GMCSF ) No concurrent filgrastim ( GCSF ) course 1 No concurrent immunotherapy Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : Must maintain stable decrease dose corticosteroid 2 week prior study Concurrent corticosteroid cerebral edema allow No concurrent anticancer hormonal therapy Radiotherapy : No prior radiotherapy No concurrent radiotherapy Surgery : At least 2 week since prior surgery Other : No concurrent investigational agent participation clinical study No concurrent immunosuppressive drug No concurrent phenobarbital valproic acid No concurrent anticonvulsants except carbamazepine gabapentin No concurrent prochlorperazine day irinotecan treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>